Edition:
United Kingdom

Koninklijke DSM NV (DSMN.AS)

DSMN.AS on Amsterdam Stock Exchange

80.42EUR
15 Dec 2017
Change (% chg)

€0.09 (+0.11%)
Prev Close
€80.33
Open
€80.37
Day's High
€80.56
Day's Low
€79.81
Volume
989,691
Avg. Vol
683,122
52-wk High
€81.17
52-wk Low
€55.11

Select another date:

Fri, Nov 17 2017

BRIEF-DSM acquires Brazilian production facility from Amyris

* DSM expands strategic alliance with Amyris and acquires Brazilian production facility from Amyris

BRIEF-DSM signs technology partnership agreement with Toyota Motorsport GmbH‍​

* SIGNS TECHNOLOGY PARTNERSHIP AGREEMENT WITH TOYOTA MOTORSPORT GMBH‍​

UPDATE 1-Dutch firm DSM reports better-than-expected rise in Q3 profit

AMSTERDAM, Nov 2 Dutch speciality chemicals company DSM on Thursday said higher sales and tighter cost controls helped third-quarter core profit rise 13 percent, to 365 million euros ($425.3 million).

Dutch firm DSM reports better-than-expected rise in Q3 profit

AMSTERDAM, Nov 2 Dutch speciality chemicals company DSM on Thursday said higher sales and tighter cost controls helped third-quarter core profit rise 13 percent, to 365 million euros ($425.3 million).

BRIEF-Amyris Inc enters into agreement with Koninklijke DSM N.V.

* Amyris enters into product development and production agreement with Royal DSM for human nutrition ingredient

BRIEF-Amyris enters into second major product development with Royal DSM

* Amyris Inc enters into second major product development and production agreement with Royal DSM

BRIEF-Amyris says second tranche of $50 mln in a private placement days is being led by a $25-mln investment from Koninklijke​

* Amyris announces agreements for $50 million in second tranche of equity financing, exceeding previous target of $95 million

UPDATE 2-DSM raises 2017 profit forecasts, shares jump

AMSTERDAM, Aug 1 Dutch speciality chemicals company DSM raised its profit forecast for 2017 on Tuesday after higher sales and tighter cost controls helped it report a better than expected 15 percent rise in second-quarter earnings.

BRIEF-Aerie Pharmaceuticals enters into collaboration agreement with DSM

* Aerie Pharmaceuticals enters into collaboration agreement with DSM focused on technology to potentially deliver Aerie compounds to treat retinal diseases such as wet AMD

BRIEF-Amyris enters into first product development, production agreement with Royal DSM

* Amyris enters into first product development and production agreement with Royal DSM for food and nutrition molecule

Select another date: